oxybutynin has been researched along with Stroke in 9 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events." | 3.30 | Cardiovascular Safety of Testosterone-Replacement Therapy. ( Basaria, S; Bhasin, S; Boden, WE; Chan, A; Cunningham, GR; Davey, D; Dubcenco, E; Flevaris, P; Granger, CB; Huang, B; Kalahasti, V; Khan, N; Khera, M; Li, X; Lincoff, AM; Miller, MG; Mitchell, LM; Nissen, SE; Pencina, KM; Snabes, MC; Thompson, IM; Travison, TG; Wang, Q; Wolski, K; Yi, T, 2023) |
| "Infections were associated with an increased risk of death (p < 0." | 2.84 | Infections Up to 76 Days After Stroke Increase Disability and Death. ( Bath, PM; Bereczki, D; Berge, E; Caso, V; Christensen, H; Collins, R; Czlonkowska, A; El Etribi, A; Farr, TD; Fone, KC; Gommans, J; Laska, AC; Learoyd, AE; Ntaios, G; Ozturk, S; Pocock, SJ; Prasad, K; Shaw, L; Sprigg, N; Trueman, RC; Wardlaw, JM; Woodhouse, L, 2017) |
| "High blood pressure is a common complication in acute stroke and is associated with a poor outcome." | 2.76 | The effect of transdermal glyceryl trinitrate on 24 h ambulatory blood pressure in acute/subacute stroke. ( Bath, AJ; Bath, PM; Geeganage, CM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lincoff, AM | 1 |
| Bhasin, S | 1 |
| Flevaris, P | 1 |
| Mitchell, LM | 1 |
| Basaria, S | 1 |
| Boden, WE | 1 |
| Cunningham, GR | 1 |
| Granger, CB | 1 |
| Khera, M | 1 |
| Thompson, IM | 1 |
| Wang, Q | 1 |
| Wolski, K | 1 |
| Davey, D | 1 |
| Kalahasti, V | 1 |
| Khan, N | 1 |
| Miller, MG | 1 |
| Snabes, MC | 1 |
| Chan, A | 1 |
| Dubcenco, E | 1 |
| Li, X | 1 |
| Yi, T | 1 |
| Huang, B | 1 |
| Pencina, KM | 1 |
| Travison, TG | 1 |
| Nissen, SE | 1 |
| Appleton, JP | 2 |
| Krishnan, K | 1 |
| Bath, PM | 4 |
| Iwano, T | 1 |
| Toda, H | 1 |
| Nakamura, K | 1 |
| Shimizu, K | 1 |
| Ejiri, K | 1 |
| Naito, Y | 1 |
| Mori, H | 1 |
| Masuda, T | 1 |
| Miyoshi, T | 1 |
| Yoshida, M | 1 |
| Hikasa, Y | 1 |
| Morimatsu, H | 1 |
| Ito, H | 1 |
| Learoyd, AE | 1 |
| Woodhouse, L | 1 |
| Shaw, L | 1 |
| Sprigg, N | 2 |
| Bereczki, D | 1 |
| Berge, E | 1 |
| Caso, V | 1 |
| Christensen, H | 1 |
| Collins, R | 1 |
| Czlonkowska, A | 1 |
| El Etribi, A | 1 |
| Farr, TD | 1 |
| Gommans, J | 1 |
| Laska, AC | 1 |
| Ntaios, G | 1 |
| Ozturk, S | 1 |
| Pocock, SJ | 1 |
| Prasad, K | 1 |
| Wardlaw, JM | 1 |
| Fone, KC | 1 |
| Trueman, RC | 1 |
| Marchitto, N | 1 |
| Sindona, F | 1 |
| Pannozzi, A | 1 |
| Dalmaso, SG | 1 |
| Anticoli, S | 1 |
| Raimondi, G | 1 |
| Mohammed, K | 1 |
| Abu Dabrh, AM | 1 |
| Benkhadra, K | 1 |
| Al Nofal, A | 1 |
| Carranza Leon, BG | 1 |
| Prokop, LJ | 1 |
| Montori, VM | 1 |
| Faubion, SS | 1 |
| Murad, MH | 1 |
| Brown, S | 1 |
| Geeganage, CM | 1 |
| Bath, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Collaborative, International, Multicentre, Randomised, Parallel-group, Single and Outcome Blinded, Controlled, Factorial Trial to Investigate the Safety and Efficacy of Treatment With Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, a[NCT00989716] | Phase 3 | 3,500 participants (Anticipated) | Interventional | 2001-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for oxybutynin and Stroke
| Article | Year |
|---|---|
Transdermal delivery of glyceryl trinitrate: clinical applications in acute stroke.
Topics: Administration, Cutaneous; Hemodynamics; Humans; Nitric Oxide Donors; Nitroglycerin; Quality of Life | 2020 |
Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Estrogen Replacement Therapy; Evidence-Based Medicine; Female; Humans; Menopau | 2015 |
Therapeutic Potential of Transdermal Glyceryl Trinitrate in the Management of Acute Stroke.
Topics: Administration, Cutaneous; Blood Pressure; Cerebrovascular Circulation; Humans; Nitric Oxide Donors; | 2017 |
4 trials available for oxybutynin and Stroke
| Article | Year |
|---|---|
Cardiovascular Safety of Testosterone-Replacement Therapy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Ge | 2023 |
Preventative effects of bisoprolol transdermal patches on postoperative atrial fibrillation in high-risk patients undergoing non-cardiac surgery: A subanalysis of the MAMACARI study.
Topics: Aged; Atrial Fibrillation; Bisoprolol; Humans; Postoperative Complications; Risk Factors; Stroke; Tr | 2021 |
Infections Up to 76 Days After Stroke Increase Disability and Death.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Incidence; Infections; Male; Middle Aged; Nitroglyce | 2017 |
The effect of transdermal glyceryl trinitrate on 24 h ambulatory blood pressure in acute/subacute stroke.
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Humans; Hypertension; Male; Nit | 2011 |
2 other studies available for oxybutynin and Stroke
| Article | Year |
|---|---|
Safety and efficacy of Rotigotine in hospedalized patients with Vascular Parkinsonism aged 75 and older: effects on movement, praxis capacities, time-space orientation, quality of life and adherence to medical therapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Brain Ischemia; Cognition; Dopamine Agonists; Fe | 2019 |
Transdermal hormone replacement therapy not associated with an increased risk of stroke.
Topics: Aged; Case-Control Studies; Female; Hormone Replacement Therapy; Humans; Longitudinal Studies; Meta- | 2010 |